View Older Stories View More Recent Stories

Sep 8, 2017 09:04AM Amgen (AMGN) to Present Latest EVENITY (Romosozumab) And Prolia (Denosumab) Research
Sep 8, 2017 09:00AM Amgen Highlights The Latest EVENITY™ (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting
Sep 7, 2017 04:31PM Amgen (AMGN) Says New Data Shows Aimovig Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies
Sep 7, 2017 04:30PM New Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies
Sep 7, 2017 04:00PM Amgen To Present At The Morgan Stanley Global Healthcare Conference
Sep 6, 2017 05:07PM Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma
Aug 31, 2017 04:01PM Amgen (AMGN) Announces EC Approval of Expanded Use of Mimpara For Treatment Of Secondary HPT in Children With End-Stage Renal Disease On Dialysis
Aug 31, 2017 04:00PM European Commission Approves Expanded Use Of Mimpara® (Cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Children With End-Stage Renal Disease On Dialysis
Aug 30, 2017 04:21PM Amgen (AMGN) Says L-T Analysis of Phase 3 Study Confirms KYPROLIS Regimen Extends Overall Survival in Relapsed Multiple Myeloma
Aug 30, 2017 04:18PM Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma
Aug 30, 2017 04:01PM Amgen (AMGN) Says FDA Accepts Filing of sNDA to Add Overall Survival Results To KYPROLIS Label
Aug 30, 2017 04:00PM FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS® (Carfilzomib) Label
Aug 29, 2017 04:01PM Amgen (AMGN) Reports New Analysis Demonstrates Repatha (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke
Aug 29, 2017 04:01PM Amgen (AMGN) Says New Virtual Histology Sub-Study Evaluates Impact of Repatha on Coronary Artery Plaque Composition
Aug 29, 2017 04:00PM New Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke
Aug 29, 2017 04:00PM New Virtual Histology Sub-Study Evaluates Impact Of Repatha® (Evolocumab) On Coronary Artery Plaque Composition
Aug 28, 2017 08:03AM Amgen (AMGN) Reports New Analysis on Repatha (evolocumab) Demonstrates Cardiovascular Outcomes Efficacy & Safety Of Achieving Very Low LDL-C Levels
Aug 28, 2017 08:00AM New Repatha® (evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels
Aug 24, 2017 04:00PM Amgen Foundation Expands The Amgen Biotech Experience, Bringing Total Program Reach To 900,000 High School Students By 2020
Aug 23, 2017 06:43PM Overall Survival Analysis From KYPROLIS® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology
Aug 23, 2017 04:02PM Amgen (AMGN) Says New Economic Analysis Based On Repatha Outcomes Data Published in JAMA Cardiology
Aug 23, 2017 04:00PM New Economic Analysis Based On Repatha® (Evolocumab) Outcomes Data Published In JAMA Cardiology
Aug 21, 2017 09:01AM Amgen (AMGN) Plans to Present New Data From The Repatha Cardiovascular Outcomes Study At ESC Congress
Aug 21, 2017 09:00AM Amgen To Present New Data From The Repatha® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017
Aug 17, 2017 04:08PM Amgen (AMGN), Humana (HUM) Partner For Improved Health Outcomes And Efficiency
Aug 17, 2017 04:00PM Amgen And Humana Partner For Improved Health Outcomes And Efficiency
Aug 16, 2017 05:14PM Amgen (AMGN) Announces Repatha Phase 3 Cognitive Function Study Results Published NEJM
Aug 16, 2017 05:10PM Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine
Jul 31, 2017 09:12AM Amgen (AMGN) Reports Submission of Supplemental Biologics License Application For Prolia (denosumab)
Jul 31, 2017 09:10AM Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis
Jul 31, 2017 09:03AM Amgen (AMGN) & Allergan (AGN) Report U.S. FDA Submission of Biosimilar Biologics License Application For ABP 980
Jul 31, 2017 09:00AM Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration
Jul 28, 2017 04:01PM Amgen Announces 2017 Third Quarter Dividend
Jul 27, 2017 05:51PM Amgen (AMGN) Says FDA Grants Priority Review For its sBLA For Repatha to Include Data On Reducing Risk Of Cardiovascular Events
Jul 27, 2017 05:49PM FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Jul 25, 2017 04:01PM Amgen Reports Second Quarter 2017 Financial Results
Jul 20, 2017 04:31PM Amgen (AMGN) Says FDA Accepted Biologics License Application For Aimovig
Jul 20, 2017 04:30PM FDA Accepts Biologics License Application For Aimovig™ (erenumab)
Jul 20, 2017 04:00PM Amgen Announces Webcast of 2017 Second Quarter Financial Results
Jul 18, 2017 08:06AM Array Biopharma (ARRY), Array BioPharma (ARRY) Announce Pact in Inflammation
Jul 18, 2017 08:00AM Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation
Jul 17, 2017 06:25AM Amgen (AMGN), UCB Announce FDA CRL for EVENITY BLA to Treat Postmenopausal Women with Osteoporosis
Jul 16, 2017 06:00PM Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US
Jul 14, 2017 09:01AM Amgen (AMGN) Submits sNDA in US And Europe to Include Overall Survival Data in KYPROLIS Label
Jul 14, 2017 09:00AM Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label
Jul 13, 2017 08:06AM Amgen (AMGN), Allergan (AGN) to Discuss Data Supporting BLA For ABP 215 with FDA
Jul 13, 2017 08:00AM Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab)
Jul 12, 2017 04:01PM Amgen (AMGN) Announces 2nd Phase 3 Study Shows KYPROLIS (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
Jul 12, 2017 04:00PM Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
Jul 12, 2017 05:37AM Amgen (AMGN) Granted FDA Approval for BLINCYTO (blinatumomab)
View More Recent Stories View Older Stories